Metastatic pituitary carcinoma in a patient with acromegaly: a case report

<p>Abstract</p> <p>Introduction</p> <p>Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adr...

Full description

Bibliographic Details
Main Authors: Sreenan Seamus, Sengupta Elizabeth, Tormey William, Landau Richard
Format: Article
Language:English
Published: BMC 2012-09-01
Series:Journal of Medical Case Reports
Subjects:
Online Access:http://www.jmedicalcasereports.com/content/6/1/322
id doaj-2d4d388187024b33b07dbaef57559f3b
record_format Article
spelling doaj-2d4d388187024b33b07dbaef57559f3b2020-11-25T00:33:28ZengBMCJournal of Medical Case Reports1752-19472012-09-016132210.1186/1752-1947-6-322Metastatic pituitary carcinoma in a patient with acromegaly: a case reportSreenan SeamusSengupta ElizabethTormey WilliamLandau Richard<p>Abstract</p> <p>Introduction</p> <p>Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adrenocorticotropic hormone, and another 24% were non-secreting.</p> <p>Case presentation</p> <p>A 42-year-old Caucasian man lived for 30 years after the diagnosis of a pituitary tumor whose clinical and biochemical features were those of acromegaly and hypogonadism. Radiotherapy, totaling 7300 rad, was administered to the sella over two courses. Growth hormone levels normalized, but he developed both thyroid and adrenal insufficiency, and replacement therapy was commenced. Fourteen years later, growth hormone levels again became elevated, and bromocriptine was commenced but led to side effects that could not be tolerated. An attempted surgical intervention failed, and octreotide and pergolide were used in succession. Twenty-seven years after the diagnosis, a mass from an excisional biopsy of below the angle of the mandible proved to be metastatic pituitary carcinoma. Immunohistochemical staining was positive for synaptophysin, growth hormone, and prolactin. One year later, an octreotide scan showed uptake at the sella, neck, and spleen. Our patient declined further active oncology treatment.</p> <p>Conclusions</p> <p>Metastatic pituitary carcinoma associated with acromegaly is particularly rare. To the best of our knowledge, this is the eighth such case and is the first report of growth hormone and prolactin present in the metastatic mass.</p> http://www.jmedicalcasereports.com/content/6/1/322Metastatic pituitary carcinomaAcromegaly
collection DOAJ
language English
format Article
sources DOAJ
author Sreenan Seamus
Sengupta Elizabeth
Tormey William
Landau Richard
spellingShingle Sreenan Seamus
Sengupta Elizabeth
Tormey William
Landau Richard
Metastatic pituitary carcinoma in a patient with acromegaly: a case report
Journal of Medical Case Reports
Metastatic pituitary carcinoma
Acromegaly
author_facet Sreenan Seamus
Sengupta Elizabeth
Tormey William
Landau Richard
author_sort Sreenan Seamus
title Metastatic pituitary carcinoma in a patient with acromegaly: a case report
title_short Metastatic pituitary carcinoma in a patient with acromegaly: a case report
title_full Metastatic pituitary carcinoma in a patient with acromegaly: a case report
title_fullStr Metastatic pituitary carcinoma in a patient with acromegaly: a case report
title_full_unstemmed Metastatic pituitary carcinoma in a patient with acromegaly: a case report
title_sort metastatic pituitary carcinoma in a patient with acromegaly: a case report
publisher BMC
series Journal of Medical Case Reports
issn 1752-1947
publishDate 2012-09-01
description <p>Abstract</p> <p>Introduction</p> <p>Asymptomatic pituitary abnormalities occur in about 10% of cranial magnetic resonance imaging scans, but metastatic carcinoma of the pituitary gland is rare: 133 cases have been reported. Two thirds secreted either prolactin or adrenocorticotropic hormone, and another 24% were non-secreting.</p> <p>Case presentation</p> <p>A 42-year-old Caucasian man lived for 30 years after the diagnosis of a pituitary tumor whose clinical and biochemical features were those of acromegaly and hypogonadism. Radiotherapy, totaling 7300 rad, was administered to the sella over two courses. Growth hormone levels normalized, but he developed both thyroid and adrenal insufficiency, and replacement therapy was commenced. Fourteen years later, growth hormone levels again became elevated, and bromocriptine was commenced but led to side effects that could not be tolerated. An attempted surgical intervention failed, and octreotide and pergolide were used in succession. Twenty-seven years after the diagnosis, a mass from an excisional biopsy of below the angle of the mandible proved to be metastatic pituitary carcinoma. Immunohistochemical staining was positive for synaptophysin, growth hormone, and prolactin. One year later, an octreotide scan showed uptake at the sella, neck, and spleen. Our patient declined further active oncology treatment.</p> <p>Conclusions</p> <p>Metastatic pituitary carcinoma associated with acromegaly is particularly rare. To the best of our knowledge, this is the eighth such case and is the first report of growth hormone and prolactin present in the metastatic mass.</p>
topic Metastatic pituitary carcinoma
Acromegaly
url http://www.jmedicalcasereports.com/content/6/1/322
work_keys_str_mv AT sreenanseamus metastaticpituitarycarcinomainapatientwithacromegalyacasereport
AT senguptaelizabeth metastaticpituitarycarcinomainapatientwithacromegalyacasereport
AT tormeywilliam metastaticpituitarycarcinomainapatientwithacromegalyacasereport
AT landaurichard metastaticpituitarycarcinomainapatientwithacromegalyacasereport
_version_ 1725316641645920256